Experts

Lisa Saylor

Associate Director, Data Management

Areas of expertise

  • Clinical research data management technical assistance
  • Social and behavioral research data management technical assistance
  • Data management training

Projects & Resources

Published Research

  • Pre-exposure prophylaxis for HIV infection among African women
    Van Damme L. Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malaheleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D on behalf of the FEM-PrEP study group
    New England Journal of Medicine. 2012; 367 (5): 411-22

    Pre-exposure prophylaxis with antiretroviral drugs has been effective in the prevention of HIV infection in some trials but not in others. This randomized, double-blind, placebo-controlled trial assigned 2,120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety. The study was stopped early, on April 18, 2011, because of lack of efficacy. Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo. Despite substantial counseling efforts, drug adherence appeared to be low.

  • Home screening for bacterial vaginosis to prevent sexually transmitted diseases
    Schwebke JR, Lee JY, Lensing S, Philip SS, Wiesenfeld HC, Sena AC, Trainor N, Acevado N, Saylor L, Rompalo AM, Cook RL
    Clin Infect Dis 2016 Mar; 62 (5): 531-6. [Journal Impact Factor: 8.886]

    These findings indicate that the treatment of asymptomatic bacterial vaginosis (BV) with oral metronidazole resulted in lower rates of future BV. There was no significant reduction in the corresponding incidence of gonorrhea or chlamydia infections. If more effective therapies for BV become available, consideration should be given to revisiting this screening approach.

Explore More Related to Lisa Saylor